An investment bank headquartered in the US does not act as a traditional investment bank, as the firm participates in venture capital, investing in and working with early-stage technology and life science companies with the main goal of taking the companies to public markets. The firm has also spun out and out-licensed technologies from universities and has capabilities to help with company formation, business strategy, IP, and early IPOs. The firm utilizes a sister company to further analyze company technologies and IPs. The firm can fund from $5-12M USD from Seed to Series A rounds with preference in US-based companies, though the firm is open to global companies.
The firm is looking at biotech, medical devices, and diagnostics companies and is technology-agnostic. The firm generally does not look at digital health. There has been strong interest in immuno-oncology, neurology, and CNS.
The firm works closely with companies and founders and will lead investment rounds. The firm typically requires taking a board or observer seat while deciding strategy, and once the company goes public, the firm will bring in a board member with expertise in the field.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment